Thrombogenicity of canine free internal mammary artery autografts

Jay P. Mashburn, Patrick M. McCarthy, Hartzell V Schaff, Mrinal K. Dewanjee

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Early patency of free internal mammary artery (IMA) grafts for coronary artery bypass (CAB) is lower than that of in situ IMA grafts, and proximal anastomotic problems have been implicated in the pathogenesis of graft occlusion. To determine whether thrombotic phenomena might account for proximal graft narrowing, we examined platelet and fibrinogen deposition in 23 free IMA grafts in a canine model of CAB. Twelve animals had no antiplatelet therapy and were controls. Eleven animals received dipyridamole, 55 mg p.o. daily, 2 days before and each day after operation; aspirin, 325 mg p.o. daily, was given after CAB. Six of the 12 untreated dogs and 5 of the 11 treated dogs were sacrificed at 1 day after surgery; the remainder of each group was sacrificed on the 14th postoperative day. Platelet and fibrinogen depositions were quantitated by indium-111 tropolone and Iodine-125 labeling, respectively. Grafts were sectioned into five parts: proximal anastomosis (PA), proximal graft (PG), midgraft (MG), distal graft (DG), and distal anastomosis (DA). Platelet deposition was highest at the PA of free IMA grafts, and fibrinogen deposition was high at both anastomoses. Antiplatelet therapy significantly reduced platelet deposition at the PA at 14 days, but not at 1 day; fibrinogen deposition was significantly reduced at the DA at 1 day, and at both the PA and DA at 14 days. The ratio of fibrinogen molecules per platelet was unaffected by antiplatelet therapy, but was observed to increase with time at the DG and DA. Unexplained discrepancies were noted in the fibrinogen-to-platelet ratio between control IMA and control femoral artery. In contrast to in situ IMA grafts, patency of free IMA grafts may be improved with antiplatelet therapy.

Original languageEnglish (US)
Pages (from-to)16-22
Number of pages7
JournalJournal of Surgical Research
Volume46
Issue number1
DOIs
StatePublished - 1989

Fingerprint

Mammary Arteries
Autografts
Canidae
Transplants
Fibrinogen
Blood Platelets
Coronary Artery Bypass
Dogs
Dipyridamole
Femoral Artery
Therapeutics
Ambulatory Surgical Procedures
Iodine
Aspirin

ASJC Scopus subject areas

  • Surgery

Cite this

Thrombogenicity of canine free internal mammary artery autografts. / Mashburn, Jay P.; McCarthy, Patrick M.; Schaff, Hartzell V; Dewanjee, Mrinal K.

In: Journal of Surgical Research, Vol. 46, No. 1, 1989, p. 16-22.

Research output: Contribution to journalArticle

Mashburn, Jay P. ; McCarthy, Patrick M. ; Schaff, Hartzell V ; Dewanjee, Mrinal K. / Thrombogenicity of canine free internal mammary artery autografts. In: Journal of Surgical Research. 1989 ; Vol. 46, No. 1. pp. 16-22.
@article{1c771866b72843ea914ca852c9d8371b,
title = "Thrombogenicity of canine free internal mammary artery autografts",
abstract = "Early patency of free internal mammary artery (IMA) grafts for coronary artery bypass (CAB) is lower than that of in situ IMA grafts, and proximal anastomotic problems have been implicated in the pathogenesis of graft occlusion. To determine whether thrombotic phenomena might account for proximal graft narrowing, we examined platelet and fibrinogen deposition in 23 free IMA grafts in a canine model of CAB. Twelve animals had no antiplatelet therapy and were controls. Eleven animals received dipyridamole, 55 mg p.o. daily, 2 days before and each day after operation; aspirin, 325 mg p.o. daily, was given after CAB. Six of the 12 untreated dogs and 5 of the 11 treated dogs were sacrificed at 1 day after surgery; the remainder of each group was sacrificed on the 14th postoperative day. Platelet and fibrinogen depositions were quantitated by indium-111 tropolone and Iodine-125 labeling, respectively. Grafts were sectioned into five parts: proximal anastomosis (PA), proximal graft (PG), midgraft (MG), distal graft (DG), and distal anastomosis (DA). Platelet deposition was highest at the PA of free IMA grafts, and fibrinogen deposition was high at both anastomoses. Antiplatelet therapy significantly reduced platelet deposition at the PA at 14 days, but not at 1 day; fibrinogen deposition was significantly reduced at the DA at 1 day, and at both the PA and DA at 14 days. The ratio of fibrinogen molecules per platelet was unaffected by antiplatelet therapy, but was observed to increase with time at the DG and DA. Unexplained discrepancies were noted in the fibrinogen-to-platelet ratio between control IMA and control femoral artery. In contrast to in situ IMA grafts, patency of free IMA grafts may be improved with antiplatelet therapy.",
author = "Mashburn, {Jay P.} and McCarthy, {Patrick M.} and Schaff, {Hartzell V} and Dewanjee, {Mrinal K.}",
year = "1989",
doi = "10.1016/0022-4804(89)90176-5",
language = "English (US)",
volume = "46",
pages = "16--22",
journal = "Journal of Surgical Research",
issn = "0022-4804",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Thrombogenicity of canine free internal mammary artery autografts

AU - Mashburn, Jay P.

AU - McCarthy, Patrick M.

AU - Schaff, Hartzell V

AU - Dewanjee, Mrinal K.

PY - 1989

Y1 - 1989

N2 - Early patency of free internal mammary artery (IMA) grafts for coronary artery bypass (CAB) is lower than that of in situ IMA grafts, and proximal anastomotic problems have been implicated in the pathogenesis of graft occlusion. To determine whether thrombotic phenomena might account for proximal graft narrowing, we examined platelet and fibrinogen deposition in 23 free IMA grafts in a canine model of CAB. Twelve animals had no antiplatelet therapy and were controls. Eleven animals received dipyridamole, 55 mg p.o. daily, 2 days before and each day after operation; aspirin, 325 mg p.o. daily, was given after CAB. Six of the 12 untreated dogs and 5 of the 11 treated dogs were sacrificed at 1 day after surgery; the remainder of each group was sacrificed on the 14th postoperative day. Platelet and fibrinogen depositions were quantitated by indium-111 tropolone and Iodine-125 labeling, respectively. Grafts were sectioned into five parts: proximal anastomosis (PA), proximal graft (PG), midgraft (MG), distal graft (DG), and distal anastomosis (DA). Platelet deposition was highest at the PA of free IMA grafts, and fibrinogen deposition was high at both anastomoses. Antiplatelet therapy significantly reduced platelet deposition at the PA at 14 days, but not at 1 day; fibrinogen deposition was significantly reduced at the DA at 1 day, and at both the PA and DA at 14 days. The ratio of fibrinogen molecules per platelet was unaffected by antiplatelet therapy, but was observed to increase with time at the DG and DA. Unexplained discrepancies were noted in the fibrinogen-to-platelet ratio between control IMA and control femoral artery. In contrast to in situ IMA grafts, patency of free IMA grafts may be improved with antiplatelet therapy.

AB - Early patency of free internal mammary artery (IMA) grafts for coronary artery bypass (CAB) is lower than that of in situ IMA grafts, and proximal anastomotic problems have been implicated in the pathogenesis of graft occlusion. To determine whether thrombotic phenomena might account for proximal graft narrowing, we examined platelet and fibrinogen deposition in 23 free IMA grafts in a canine model of CAB. Twelve animals had no antiplatelet therapy and were controls. Eleven animals received dipyridamole, 55 mg p.o. daily, 2 days before and each day after operation; aspirin, 325 mg p.o. daily, was given after CAB. Six of the 12 untreated dogs and 5 of the 11 treated dogs were sacrificed at 1 day after surgery; the remainder of each group was sacrificed on the 14th postoperative day. Platelet and fibrinogen depositions were quantitated by indium-111 tropolone and Iodine-125 labeling, respectively. Grafts were sectioned into five parts: proximal anastomosis (PA), proximal graft (PG), midgraft (MG), distal graft (DG), and distal anastomosis (DA). Platelet deposition was highest at the PA of free IMA grafts, and fibrinogen deposition was high at both anastomoses. Antiplatelet therapy significantly reduced platelet deposition at the PA at 14 days, but not at 1 day; fibrinogen deposition was significantly reduced at the DA at 1 day, and at both the PA and DA at 14 days. The ratio of fibrinogen molecules per platelet was unaffected by antiplatelet therapy, but was observed to increase with time at the DG and DA. Unexplained discrepancies were noted in the fibrinogen-to-platelet ratio between control IMA and control femoral artery. In contrast to in situ IMA grafts, patency of free IMA grafts may be improved with antiplatelet therapy.

UR - http://www.scopus.com/inward/record.url?scp=0024587272&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024587272&partnerID=8YFLogxK

U2 - 10.1016/0022-4804(89)90176-5

DO - 10.1016/0022-4804(89)90176-5

M3 - Article

C2 - 2783750

AN - SCOPUS:0024587272

VL - 46

SP - 16

EP - 22

JO - Journal of Surgical Research

JF - Journal of Surgical Research

SN - 0022-4804

IS - 1

ER -